Abstract Title: Biomarker analysis from Phase 2 study of AgenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1 refractory ...
Windtree Therapeutics (WINT) announced that an istaroxime presentation featuring the positive Phase 2b SEISMiC study was given on February 11, ...
How to reflect brand values and appeal to your target audience - The secret to designing a logo that leaves a lasting impression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback